These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8568125)

  • 21. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
    Lombardo T; Ferro G; Frontini V; Percolla S
    Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful parenteral desensitization to paclitaxel.
    Essayan DM; Kagey-Sobotka A; Colarusso PJ; Lichtenstein LM; Ozols RF; King ED
    J Allergy Clin Immunol; 1996 Jan; 97(1 Pt 1):42-6. PubMed ID: 8568136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Case report 744. Deferoxamine-induced skeletal dysplasia.
    Borenstein ZC; Hyman CB; Rimoin DL; Chapman CL; Lachman R
    Skeletal Radiol; 1992; 21(8):534-7. PubMed ID: 1465648
    [No Abstract]   [Full Text] [Related]  

  • 24. Acute renal failure following deferoxamine overdose.
    Li Volti S; Maccarone C; Li Volti G; Romeo MA
    Pediatr Nephrol; 2003 Oct; 18(10):1078-9. PubMed ID: 12920634
    [No Abstract]   [Full Text] [Related]  

  • 25. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
    Gharagozloo M; Moayedi B; Zakerinia M; Hamidi M; Karimi M; Maracy M; Amirghofran Z
    Fundam Clin Pharmacol; 2009 Jun; 23(3):359-65. PubMed ID: 19453758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sensorineural hearing loss in β-thalassemia patients treated with iron chelation.
    Osma U; Kurtoglu E; Eyigor H; Yilmaz MD; Aygener N
    Ear Nose Throat J; 2015 Dec; 94(12):481-5. PubMed ID: 26670754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
    Haghpanah S; Zarei T; Zahedi Z; Karimi M
    Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute renal failure occurring during intravenous desferrioxamine therapy: recovery after haemodialysis.
    Cianciulli P; Sorrentino F; Forte L; Palombi M; Papa G; Meloni C; Taccone Gallucci M; Casciani CU
    Haematologica; 1992; 77(6):514-5. PubMed ID: 1289188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hepatic abscess due to Yersinia in a child with thalassemia].
    Brunel F; François P; Durand C; Croize J; Jeannoel P
    Pediatrie; 1993; 48(2):159-62. PubMed ID: 8393182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined therapy with deferiprone and desferrioxamine in thalassemia major.
    Loukopoulos D
    Haematologica; 2005 Oct; 90(10):1304-5. PubMed ID: 16219564
    [No Abstract]   [Full Text] [Related]  

  • 31. Behavioral contracting to improve adherence in patients with thalassemia.
    Koch DA; Giardina PJ; Ryan M; MacQueen M; Hilgartner MW
    J Pediatr Nurs; 1993 Apr; 8(2):106-11. PubMed ID: 8509968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypersensitivity to cyclosporine (Neoral) and successful desensitization.
    Sumpton JE; White CT; Rieder MJ; D'Souza SJ
    Transplant Proc; 2001 Sep; 33(6):3015-7. PubMed ID: 11543829
    [No Abstract]   [Full Text] [Related]  

  • 33. Antihistone and other autoantibodies in beta-thalassemia major patients receiving iron chelators.
    Pradhan V; Badakere S; Ghosh K
    Acta Haematol; 2003; 109(1):35-9. PubMed ID: 12486321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
    Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Marrow proliferation as a cause of hearing loss in beta-thalassaemia major.
    Thio D; Prasad V; Anslow P; Lennox P
    J Laryngol Otol; 2008 Nov; 122(11):1253-6. PubMed ID: 17931455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone.
    Loebstein R; Dalal I; Nisbet-Brown E; Berkovitch M; Meydan N; Andrews D; Loubser MD; Koren G; Roifman CM; Olivieri NF
    Br J Haematol; 1997 Sep; 98(3):597-600. PubMed ID: 9332313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anaphylactic reaction to desferrioxamine.
    Athanasion A; Shepp MA; Necheles TF
    Lancet; 1977 Sep; 2(8038):616. PubMed ID: 71438
    [No Abstract]   [Full Text] [Related]  

  • 38. Rapid development of severe toxic retinopathy associated with continuous intravenous deferoxamine infusion.
    Lai TY; Lee GK; Chan WM; Lam DS
    Br J Ophthalmol; 2006 Feb; 90(2):243-4. PubMed ID: 16424543
    [No Abstract]   [Full Text] [Related]  

  • 39. Growth failure and bone lesions due to desferrioxamine in thalassaemic patients.
    Caruso-Nicoletti M; Di Bella D; Pizzarelli G; Leonardi C; Sciuto C; Coco M; Di Gregorio F
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():957-60. PubMed ID: 10091171
    [No Abstract]   [Full Text] [Related]  

  • 40. [Ocular findings in Desferal therapy].
    Dennerlein JA; Lang GE; Stahnke K; Kleihauer E; Lang GK
    Ophthalmologe; 1995 Feb; 92(1):38-42. PubMed ID: 7719074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.